Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Bladder Dysfunction Reports
Published in: Current Bladder Dysfunction Reports 4/2019

01-12-2019 | Overactive Bladder | Overactive Bladder (U Lee and S Adelstein, Section Editors)

Overactive Bladder in Diabetes Mellitus

Authors: Vaishnavi Narayanamurthy, Emily A. Slopnick, David D. Sheyn, Laura Bukavina, Kirtishri Mishra, Adonis K. Hijaz

Published in: Current Bladder Dysfunction Reports | Issue 4/2019

Login to get access

Abstract

Purpose of Review

To explore the current literature regarding the epidemiology, pathophysiology, diagnosis, and management of overactive bladder in diabetic patients.

Recent Findings

Overactive bladder is a syndrome complex of urinary urgency, often accompanied by frequency and nocturia. Several studies have established the relationship between diabetes mellitus and bladder dysfunction. However, there is limited literature available to evaluate the prevalence of overactive bladder in this population and to guide clinical practice. The introduction of medications such as mirabegron and minimally invasive techniques such as intravesicular onabotulinumtoxinA injections has resulted in a shift in the treatment model for overactive bladder. New technologies for treatment such as radiofrequency therapy are also under active development. Ongoing research seeks to further understand the mechanisms involved in the pathogenesis of overactive bladder and identify biomarkers.

Summary

With the increasing prevalence of diabetes mellitus, it is expected that patients with overactive bladder symptoms will be seen more frequently. The American Urological Association (AUA) and Society of Urodynamics and the Female Pelvic Medicine & Urogenital Reconstruction (SUFU) recently updated the guidelines for the diagnosis for overactive bladder in 2019. However, there are important considerations in diabetic patients that may alter clinical evaluation and management. We tried to shed some light on these diagnostic considerations and the management options available to diabetic patients.
Literature
1.
2.
3.
4.
Daneshgari F, Liu G, Hanna-Mitchell AT. Path of translational discovery of urological complications of obesity and diabetes. Am J Physiol Physiol. 2017;312:F887–96.CrossRef
5.
Haylen BT, de Ridder D, Freeman RM, et al. An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2009;21:5–26.
6.
Stewart W, van Rooyen J, Cundiff G, Abrams P, Herzog A, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 20:327–36.PubMedCrossRef
7.
Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National Community Prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77:1081–7.PubMedCrossRef
8.
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–15.PubMedCrossRef
9.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–6.PubMedCrossRef
10.
Eapen RS, Radomski SB. Gender differences in overactive bladder. Can J Urol. 2016;23:2–9.PubMed
11.
Palleschi G, Pastore AL, Maggioni C, Fuschi A, Pacini L, Petrozza V, et al. Overactive bladder in diabetes mellitus patients: a questionnaire-based observational investigation. World J Urol. 2014;32:1021–5.PubMedCrossRef
12.
Liu R-T, Chung M-S, Lee W-C, Chang S-W, Huang S-T, Yang KD, et al. Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes. Urology. 2011;78:1040–5.PubMedCrossRef
13.
Xu D, Gao J, Wang X, Huang L, Wang K. Prevalence of overactive bladder and its impact on quality of life in 1025 patients with type 2 diabetes in mainland China. J Diabetes Complicat. 2017;31:1254–8.CrossRef
14.
Birder LA. Urinary bladder, cystitis and nerve/urothelial interactions. Auton Neurosci. 2014;182:89–94.PubMedCrossRef
15.
Klee NS, McCarthy CG, Lewis S, McKenzie JL, Vincent JE, Webb RC. Urothelial senescence in the pathophysiology of diabetic bladder dysfunction—a novel hypothesis. Front Surg. 2018;5:72.PubMedPubMedCentralCrossRef
16.
Mustafa S. Effect of diabetes on the ion pumps of the bladder. Urology. 2013;81:211.e17–21.CrossRef
17.
Kendig DM, Ets HK, Moreland RS. Effect of type II diabetes on male rat bladder contractility. Am J Physiol Physiol. 2016;310:F909–22.CrossRef
18.
Inouye BM, Hughes FM Jr, Jin H, Lütolf R, Potnis KC, Routh JC, et al. Diabetic bladder dysfunction is associated with bladder inflammation triggered through hyperglycemia, not polyuria. Res Rep Urol. 2018;10:219–25.PubMedPubMedCentral
19.
Szasz T, Wenceslau CF, Burgess B, Nunes KP, Webb RC. Toll-like receptor 4 activation contributes to diabetic bladder dysfunction in a murine model of type 1 diabetes. Diabetes. 2016;65:3754–64.PubMedPubMedCentralCrossRef
20.
Hanna-Mitchell AT, Ruiz GW, Daneshgari F, Liu G, Apodaca G, Birder LA. Impact of diabetes mellitus on bladder uroepithelial cells. Am J Physiol Integr Comp Physiol. 2013;304:R84–93.CrossRef
21.
Wang D, Yuan X, Hu C, Zhang B, Gao H, Wang D, et al. Endoplasmic reticulum stress is involved in apoptosis of detrusor muscle in streptozocin-induced diabetic rats. Neurourol Urodyn. 2017;36:65–72.PubMedCrossRef
22.
Daneshgari F, Liu G, Imrey PB. Time dependent changes in diabetic Cystopathy in rats include compensated and decompensated bladder function. J Urol. 2006;176:380–6.PubMedCrossRef
23.
24.
Abu-Ashour W, Twells LK, Valcour JE, Gamble J-M. Diabetes and the occurrence of infection in primary care: a matched cohort study. BMC Infect Dis. 2018;18:67.PubMedPubMedCentralCrossRef
25.
• Davenport A, Stark S, Quian A, Sheyn D, Mangel J. A patient-centered approach to refractory overactive bladder and barriers to third-line therapy. Obstet Gynecol. 2019;134:141–8 Importance of patient education in management and treatment compliance of OAB. PubMedCrossRef
26.
Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, et al. Lifestyle intervention is associated with lower prevalence of urinary incontinence: the diabetes prevention program. Diabetes Care. 2006;29:385–90.PubMedCrossRef
27.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMedCrossRef
28.
Phelan S, Kanaya AM, Ma Y, et al. Long-term prevalence and predictors of urinary incontinence among women in the diabetes prevention program outcomes study. Int J Urol. 2015;22:206–12.PubMedCrossRef
29.
Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2018;10:CD005654.PubMed
30.
31.
Yang Y-W, Liu H-H, Lin T-H, Chuang H-Y, Hsieh T. Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus. PLoS One. 2017;12:e0175335.PubMedPubMedCentralCrossRef
32.
Cetinel B, Onal B. Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean J Urol. 2013;54:806–15.PubMedPubMedCentralCrossRef
33.
• Gratzke C, van Maanen R, Chapple C, et al. Long-term safety and efficacy of Mirabegron and Solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). Eur Urol. 2018;74:501–9 SYNERGY II trial demonstrated efficacy and safety of combination treament using Mirabegron and Solifenacin. PubMedCrossRef
34.
Gaziev G, Topazio L, Iacovelli V, Asimakopoulos A, Di Santo A, De Nunzio C, et al. Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol. 2013;13:61.PubMedPubMedCentralCrossRef
35.
Levin PJ, Wu JM, Kawasaki A, Weidner AC, Amundsen CL. The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review. Int Urogynecol J. 2012;23:1591–7.PubMedCrossRef
36.
Moossdorff-Steinhauser HFA, Berghmans B. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review. Neurourol Urodyn. 2013;32:206–14.PubMedCrossRef
37.
Mathieu L, Peyronnet B, Senal N, Fontaine S, Manunta A, Honoré T, et al. [outcomes of transcutaneous posterior tibial nerve stimulation for overactive bladder in diabetic patients]. Article in French. Prog Urol. 2017;27:1091–7.PubMedCrossRef
38.
Cui Y, Wang L, Liu L, Zeng F, Niu J, Qi L, et al. Botulinum toxin-a injections for idiopathic overactive bladder: a systematic review and meta-analysis. Urol Int. 2013;91:429–38.PubMedCrossRef
39.
Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111:106–13.PubMedCrossRef
40.
Veeratterapillay R, Harding C, Teo L, Vasdev N, Abroaf A, Dorkin TJ, et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type a injections for detrusor overactivity. Int J Urol. 2014;21:175–8.PubMedCrossRef
41.
Ravindra P, Jackson BL, Parkinson RJ. Botulinum toxin type a for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox ® ) or abobotulinumtoxinA (Dysport ® ) make a difference? BJU Int. 2013;112:94–9.PubMedCrossRef
42.
Wang C-C, Liao C-H, Kuo H-C. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxina injection in patients with refractory detrusor overactivity. Neurourol Urodyn. 2014;33:1235–9.PubMedCrossRef
43.
Osborn DJ, Kaufman MR, Mock S, Guan MJ, Dmochowski RR, Reynolds WS. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourol Urodyn. 2015;34:675–8.PubMedCrossRef
44.
Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34:224–30.PubMedCrossRef
45.
Peters KM, Shen L, McGuire M. Effect of sacral neuromodulation rate on overactive bladder symptoms: a randomized crossover feasibility study. Low Urin Tract Symptoms. 2013;5:129–33.PubMedCrossRef
46.
Davis T, Makovey I, Guralnick ML, O’Connor RC. Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: lack of anticholinergic efficacy versus intolerability. Can Urol Assoc J. 2013;7:176–8.PubMedPubMedCentralCrossRef
47.
Angioli R, Montera R, Plotti F, Aloisi A, Montone E, Zullo MA. Success rates, quality of life, and feasibility of sacral nerve stimulation in elderly patients: 1-year follow-up. Int Urogynecol J. 2013;24:789–94.PubMedCrossRef
48.
Lai HH, Grewal S. Bacterial colonization rate of InterStim and infection outcome with staged testing. Urology. 2013;82:1255–60.PubMedCrossRef
49.
Daniels DH, Powell CR, Braasch MR, Kreder KJ. Sacral neuromodulation in diabetic patients: success and complications in the treatment of voiding dysfunction. Neurourol Urodyn. 2009;29:578–81.CrossRef
50.
•• Suh YS, Ko KJ, Kim TH, Lee HS, Sung HH, Cho WJ, et al. Potential biomarkers for diagnosis of overactive bladder patients: urinary nerve growth factor, prostaglandin E2, and adenosine triphosphate. Int Neurourol J. 2017;21:171–7 Urinary nerve growth factor is a potential biomarker for diagnosis of OAB. PubMedPubMedCentralCrossRef
51.
•• Park EC, Lim JS, Kim S II, et al. proteomic analysis of urothelium of rats with Detrusor overactivity induced by bladder outlet obstruction. Mol Cell Proteomics. 2018;17:948–60 Proteins expressed in the urothelium may serve as potential biomarkers. PubMedPubMedCentralCrossRef
52.
Fırat E, Aybek Z, Akgün Ş, Küçüker K, Akça H, Aybek H. Exploring biomarkers in the overactive bladder: alterations in miRNA levels of a panel of genes in patients with OAB. Neurourol Urodyn. 2019;38:1571–8.PubMedCrossRef
53.
Guzman-Negron JM, Goldman HB. New devices and Technologies for the Management of overactive bladder. Curr Urol Rep. 2017;18:94.PubMedCrossRef
54.
Balthazar A, Cullingsworth ZE, Nandanan N, Anele U, Swavely NR, Speich JE, et al. An external compress-release protocol induces dynamic elasticity in the porcine bladder: a novel technique for the treatment of overactive bladder? Neurourol Urodyn. 2019;38:1222–8.PubMedPubMedCentralCrossRef
Metadata
Title
Overactive Bladder in Diabetes Mellitus
Authors
Vaishnavi Narayanamurthy
Emily A. Slopnick
David D. Sheyn
Laura Bukavina
Kirtishri Mishra
Adonis K. Hijaz
Publication date
01-12-2019
Publisher
Springer US
Published in
Current Bladder Dysfunction Reports / Issue 4/2019
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-019-00532-9

Other articles of this Issue 4/2019

Current Bladder Dysfunction Reports 4/2019 Go to the issue

Pharmacotherapies and Drug Development/Agents (ES Rovner, Section Editor)

Nocturia: Evaluation and Management

Neurogenic Bladder (C Powell, Section Editor)

Combination Therapy for Bladder Dysfunction in Patients with Neurogenic Detrusor Overactivity

Pharmacotherapies and Drug Development/Agents (ES Rovner, Section Editor)

Pharmacotherapy for Interstitial Cystitis/Bladder Pain Syndrome

BPS/Interstitial Cystitis (D Castro-Diaz and Y Igawa, Section Editors)

Recent Developments in Imaging in BPS/IC

Stress Incontinence and Prolapse (WS Reynolds, Section Editor)

Hormone Replacement for Pelvic Floor Disorders

Cancer-Associated Voiding Dysfunction (S Elliott and J Pariser, Section Editor)

Rectourethral Fistula—Review of Current Practices, Developments, and Outcomes